Secukinumab-induced alopecia totalis in a patient with erythrodermic psoriasis
10.3760/cma.j.cn114015-20240929-00066
- VernacularTitle:司库奇尤单抗致红皮病型银屑病患者全秃
- Author:
Jingyue MA
1
;
Xin ZHENG
1
;
Huiping WANG
1
Author Information
1. 天津医科大学总医院皮肤性病科/天津性传播疾病研究所，天津 300052
- Publication Type:Journal Article
- Keywords:
Psoriasis;
Secukinumab;
Interleukin-17 inhibitors;
Alopecia totalis
- From:
Adverse Drug Reactions Journal
2025;27(7):435-437
- CountryChina
- Language:Chinese
-
Abstract:
A 67-year-old female patient with erythrodermic psoriasis showed no significant improvement in rash after 2 weeks of treatments with acitretin, ebastine, etc., with the psoriasis area and severity index (PASI) score of 72 points (the highest value). Secukinumab 300 mg once a week was given by subcutaneous injection, which was changed to 300 mg once a month after 5 weeks of medication. After 5 weeks of treatment(medication 5 times), the patient′s PASI improvement rate was 75%, but the patient developed alopecia areata and her eyebrows fall off. After 6 months of treatment, the PASI improvement rate was 100%, but the patient developed alopecia totalis and her eyebrows completely disappeared. During the 9-month follow-up, the patient did not stop taking medication or received hair loss treatment. No psoriasis rash recurred and her hair loss was not improved.
